Format

Send to

Choose Destination
Virchows Arch. 2012 Sep;461(3):245-57. doi: 10.1007/s00428-012-1281-4. Epub 2012 Jul 24.

EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations.

Author information

1
Department of Pathology, VU University Medical Centre, Amsterdam, The Netherlands. e.thunnissen@vumc.nl

Abstract

In non-small cell lung cancer, epidermal growth factor receptor gene mutations and anaplastic lymphoma kinase (ALK) gene rearrangements have a major impact upon the level of response to treatment with specific tyrosine kinase inhibitors. This review describes the molecular basis of ALK inhibition, summarizes current data on the effectiveness and safety of ALK inhibition therapy, describes the different testing methodologies with their advantages and disadvantages, provides a suggested testing algorithm and puts forward a proposal for an external quality assessment program in ALK testing.

PMID:
22825000
PMCID:
PMC3432214
DOI:
10.1007/s00428-012-1281-4
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center